

Special Issue

Vaccination Against Viral Hepatitis for Prevention and Treatment

Message from the Guest Editors

The World Health Organisation estimated that Hepatitis B and C viruses caused over a million deaths in 2022 with 304 million people chronically infected worldwide. There are >20 million hepatitis A and E virus infections each year, often resulting in debilitating symptoms and sometimes fulminant hepatitis. Vaccines play a central role in controlling viral hepatitis and reaching the WHO 2030 target to reduce new hepatitis infections by 90% from 2015 levels. This Special Issue aims to bring together original research articles and reviews on viral hepatitis and recent exciting advances:

- Strategies to increase coverage of existing viral hepatitis vaccines;
- Research into new prophylactic and therapeutic viral hepatitis vaccines, formulations, and delivery mechanisms;
- Ways to enhance the immunogenicity or safety of viral hepatitis vaccines;
- Immune responses to viral hepatitis vaccines;
- Epidemiological impact studies of viral hepatitis vaccines.

Guest Editors

Dr. Antony Black

School of Life Sciences, University of Westminster, London, UK

Dr. Monique Andersson

Department of Infection, University of Oxford, Oxford University Hospitals NHS Foundation Trust, Oxford, UK

Deadline for manuscript submissions

31 December 2025



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/226606

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).